(Q36376841)

13 August 2017

1 reference

title

Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient (English)

1 reference

13 August 2017

1 reference

W Jonat

1

1 reference

13 August 2017

K I Pritchard

series ordinal

2

1 reference

13 August 2017

R Sainsbury

series ordinal

3

1 reference

13 August 2017

J G Klijn

series ordinal

4

1 reference

13 August 2017

publication date

25 January 2006

1 reference

Journal of Cancer Research and Clinical Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

132

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

275-286

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-006-0082-z

13 August 2017

exact match

0 references

cites work

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-006-0082-Z

Mitoxantrone: a new anticancer drug with significant clinical activity

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-006-0082-Z

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-006-0082-Z

Life after breast cancer: understanding women's health-related quality of life and sexual functioning

21 January 2018

1 reference

12 December 2020

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

1 reference

12 December 2020

Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic

1 reference

12 December 2020

Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Grou

1 reference

12 December 2020

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

1 reference

12 December 2020

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

1 reference

12 December 2020

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

1 reference

12 December 2020

Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast canc

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

12 December 2020

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

12 December 2020

Cancer statistics, 2003.

1 reference

12 December 2020

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

1 reference

12 December 2020

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

12 December 2020

Adjuvant docetaxel for node-positive breast cancer

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Taxanes in adjuvant breast cancer setting: which standard in Europe?

1 reference

12 December 2020

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

1 reference

12 December 2020

Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions

1 reference

12 December 2020

Cardiac toxicity from antitumor therapy

1 reference

12 December 2020

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

1 reference

12 December 2020

Guidelines on endocrine therapy of breast cancer EUSOMA.

1 reference

12 December 2020

Primary care for survivors of breast cancer

1 reference

12 December 2020

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

1 reference

12 December 2020

Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications

1 reference

12 December 2020

Breast cancer diagnosis and screening

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

1 reference

12 December 2020

Adjuvant chemotherapy for breast cancer: an update.

1 reference

12 December 2020

Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer

1 reference

12 December 2020

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer

1 reference

12 December 2020

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

12 December 2020

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

12 December 2020

Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study.

1 reference

12 December 2020

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

1 reference

12 December 2020

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

12 December 2020

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study

1 reference

12 December 2020

Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer

1 reference

12 December 2020

Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study

1 reference

12 December 2020

Optimizing the use of anthracyclines in the adjuvant treatment of early-stage breast cancer

1 reference

12 December 2020

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

12 December 2020

Taxanes in the adjuvant treatment of breast cancer: why not yet?

1 reference

12 December 2020

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

12 December 2020

10.1007/S00432-006-0082-Z

Identifiers

DOI

1 reference

13 August 2017

1 reference